TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)—A multicenter, randomized phase II trial in progress.
Andreas Berger
No relevant relationships to disclose
Thomas Ettrich
No relevant relationships to disclose
Angela Marten
Employment or Leadership Position - Boehringer Ingelheim
Other Remuneration - Boehringer Ingelheim
Thomas Seufferlein
No relevant relationships to disclose